Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PBI-220
- Development stage
- Preclinical
- Lead developer
- Planet Biotechnology
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Receptor-Fc Fusions → Fc Fusion Proteins → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
PBI-220 is a recombinant immunoadhesin protein developed by Planet Biotechnology for the treatment and prevention of inhalational anthrax. It is a fusion protein consisting of the extracellular domain of the human anthrax toxin receptor, Capillary Morphogenesis Gene 2 (CMG2), and the Fc region of human IgG. Produced using a proprietary plant-based expression platform, PBI-220 functions as a high-affinity decoy receptor. It binds to and neutralizes the protective antigen (PA) component of the anthrax toxin, thereby preventing the toxin from binding to cellular receptors and entering host cells. Preclinical studies in rabbit and non-human primate models have demonstrated high survival rates following lethal exposure to Bacillus anthracis spores.
- Other names
- CMG2-FcCMG-2-FcCMG 2-Fcanthrax toxin receptor-Fc fusion protein
02
Targets
PA (Influenza polymerase acidic protein)
Beyond the preview
Go deeper on PBI-220.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PBI-220.